Nanomedicines modulating tumor immunosuppressive cells to enhance cancer immunotherapy.

ABSTRACT: Cancer immunotherapy has veered the paradigm of cancer treatment. Despite recent advances in immunotherapy for improved antitumor efficacy, the complicated tumor microenvironment (TME) is highly immunosuppressive, yielding both astounding and unsatisfactory clinical successes. In this regard, clinical outcomes of currently available immunotherapy are confined to the varied immune systems owing in large part to the lack of understanding of the complexity and diversity of the immune context of the TME. Various advanced designs of nanomedicines could still not fully surmount the delivery barriers of the TME. The immunosuppressive TME may even dampen the efficacy of antitumor immunity. Recently, some nanotechnology-related strategies have been inaugurated to modulate the immunosuppressive cell

SUBMITTER: Zhu Y 

PROVIDER: S-EPMC7714985 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature